EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

SLD Summit 2023

 

21-23 September Prague
Close
N. Poster
Poster title
Applicant name
Status
  PO5-1 Association of liver fibrosis with emerging extrahepatic cancer in fatty liver patients with the PNPLA3 I148M GG genotype: an 8-year cohort study MINGLING CHANG Received Received
  PO4-1 Diagnosing metabolic associated steatotic liver disease in primary care patients with type 2 diabetes mellitus - a novel, algorithm based approach Damien Leith Received Received
  PO7-1 Association between cardiovascular disease risk factors and metabolic dysfunction-associated steatotic liver disease among rheumatoid arthritis patients Alina Saidi Received Received
  PO3-1 PNPLA3 is associated to FIB-4 but not to (cardiovascular) mortality in an elderly population: report from the PROSPER trial Vivian de Jong Received Received
  PO1-1 DMF-activated Nrf2 ameliorates palmitic acid toxicity in hepatocytes while potentiates ferroptosis: independent protection by NO-donors Diana Abu halaka Received Received
  PO2-1 Low implementation rates of the American Gastroenterology Association (AGA) clinical care pathway in gastroenterology practice. Pollard Nina Received Received
  PO6-1 A 5 sit-to-stand test may identify MASLD patients at higher risk for worse clinical outcomes Roberta Forlano Received Received
  PO2-2 Efficacy of metabolyteTM treatment for MASH prevention and reversal Giulia Angelini Received Received
  PO7-2 Lobular inflammation, but no NAS score, is associated with higher risk of progression to cirrhosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) Giordano Sigon Received Received
  PO5-2 The correlation between the LDL level and the development of NAFLD MOHAMED SHAFI MAHBOOB ALI Received Received
  PO4-2 Diabetic advanced steatotic liver disease is a surrogate for the other complications of type 2 diabetes mellitus Zülal Istemihan Received Received
  PO1-2 The impact of artificial intelligence on the evaluation of fibrosis changes in steatotic liver diseases: a single center experience Reha Akpinar Received Received
  PO3-2 Steatotic liver disease and risk of hepatocellular carcinoma in hepatitis B and C infected individuals: a systematic review and meta-analysis Muhammed Elfaituri Received Received
  PO4-3 The PNPLA3 genotype of MASLD patients profoundly alters their metabolic profile even with a low BMI Lina Jegodzinski Received Received
  PO6-3 Association between hepatic artery resistance index (HARI), portal venous pulsatility index (PVPI) and steatotic liver disease (SLD) fibrotic score in SLD patients Simu Razvan-Ioan Received Received
  PO2-3 RIPK3 modulates acyl chain structure in metabolic liver disease André Cardador Received Received
  PO7-3 Disruption of hepatic integrity and lipid composition by hypercaloric diets in steatotic liver disease Maria Joao Meneses Received Received
  PO3-3 Shared genetics between NAFLD and Parkinsons disease: the role of TLR4 signaling pathway Christina Flourou Received Received
  PO5-3 Impact of exercise training on hepatic lipid composition in men with MASLD and impaired glycaemic regulation: a pilot randomised controlled trial Sundus Malaikah Received Received
  PO1-3 The effects of vitamin E and docosahexaenoic acid ethyl ester on nonalcoholic fatty liver disease (NAFLD) - a randomized double blind placebo controlled parallel group clinical trial (PUVENAFLD) Naim Alkhouri Received Received
  PO6-4 miR-21-5p promotes MASH-related hepatocarcinogenesis Pedro Miguel Rodrigues Received Received
  PO5-4 Assessing hepatocellular senescence in metabolic dysfunction-associated liver disease using a quantitative approach Roberta Forlano Received Received
  PO3-4 The natural history of metabolic dysfunction-associated steatotic liver disease with advanced fibrosis Zouhir Gadi Received Received
  PO7-4 Liver steatosis and fibrosis in severe obesity in diabetic and non-diabetic subjects: first report of the Franciscus obesity NASH Study Willy Theel Received Received
  PO4-4 Genetic markers of MASLD in an elderly Caucasian population and the association with obesity Willy Theel Received Received
  PO1-4 The long term safety and efficacy of Saroglitazar in metabolic dysfunction-associated steatohepatitis (MASH) related compensated cirrhosis: a prospective, single center real life experience Sujit Chaudhuri Received Received
  PO5-5 Transcriptomics driven metabolic pathway analysis to explore metabolic resemblance between metabolic-dysfunction associated steatohepatitis mouse models and human Mojgan Masoodi Received Received
  PO2-5 Steatotic liver disease and SGLT2 inhibitors: improvement of hepatic fibrosis by Fibroscan in a prospective study Jaqueline Curra Received Received
  PO1-5 Open data, explainable AI, data science and conventional NITs the recipe for new machine learning diagnostic tests on MASLD Athanasios Angelakis Received Received
  PO4-5 Single-cell profiling of hepatic dendritic cells in metabolic dysfunction-associated steatotic liver disease Camilla Klaimi Received Received
  PO7-5 Thermoacoustic assessment of fatty liver disease - a clinical feasibility study Michael Thornton Received Received
  PO6-5 Changes in lipid metabolism and insulin resistance after an oral lipid load in patients with metabolic dysfunction associated steatotic liver disease (MASLD) carrying the PNPLA3 rs738409 polymorphism Chiara Rosso Received Received
  PO6-6 Analytical and clinical comparison of three non-invasive tests for the diagnosis of metabolic dysfunction-associated steatohepatitis (MASH) Silvia Sabatini Received Received
  PO1-6 Validation of HeparDx score (by Metadeq, Inc.) as a non-invasive test for the diagnosis of metabolic dysfunction-associated steatohepatitis (MASH) Giulia Angelini Received Received
  PO7-6 Risk factors for progression in metabolic dysfunction-associated steatotic liver disease Letitia Toma Received Received
  PO4-6 Unleashing the potential of phytocannabinoids in modulating sphingolipid homeostasis for the treatment of metabolic dysfunction-associated steatotic liver disease Radka Kocvarova Received Received
  PO2-7 Transcriptomics-assisted phenotypic screening to identify novel drugs and targets for liver fibrosis Elisabetta De Filippo Received Received
  PO1-7 Poor diet quality is associated with higher liver stiffness and higher cardiovascular risk in a cohort of Italian MASLD (metabolic dysfunction associated steatotic liver disease) outpatients Rusi Chen Received Received
  PO4-7 MASLD and chronic viral hepatitis: baseline results from patients enrolled in the PITER HCV and HBV and HDV italian cohorts Loreta A. Kondili Received Received
  PO7-7 Quantitative assessment of liver steatosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) based on plasma extracellular vesicles in correlation with ultrasound attenuation parameter (UAP). Eleni Myrto Trifylli Received Received
  PO6-7 The association of liver fibrosis, insulin resistance and systemic leukocyte activation in obese patients Alina Saidi Received Received
  PO5-7 Hypoxanthine plasma levels as a new potential non-invasive biomarker of metabolic-dysfunction associated steatotic liver disease Melissa Maria Milito Received Received
  PO3-7 Behavioural specifics of patients living with non-alcoholic fatty liver disease/metabolic dysfunction-associated steatotic liver disease a key to improve communication Andreas Geier Received Received
  PO2-8 Statin treatment reduces all-cause mortality in elderly with increased risk of liver fibrosis: report from the PROSPER trial Vivian de Jong Received Received
  PO4-8 Comparison of the efficacy of MR spectroscopic and MR imaging methods for assessing liver fat changes in obese patients undergoing dietary intervention and GLP-1 agonist treatment Petr Kordac Received Received
  PO1-8 Galectin-3 inhibitor prevents metabolic dysfunction-association steatohepatitis and insulin resistance in western diet-fed ApoE knockout mice Layanne Araujo Received Received
  PO6-8 The potential role of Omentin-1 in metabolic-dysfunction associated steatotic liver disease (MASLD): evidence from translational studies Noel Salvoza Received Received
  PO7-8 Novel compound SNP-6 series active metabolites mitigate nonalcoholic steatohepatitis and fibrosis: results from preclinical models and a phase 2a clinical trial Chang-Hui Tsao Received Received
  PO3-8 Culturally adapting the mediterranean diet for the hispanic and latino population in the weight intervention in liver disease (WILD) clinical pathway Sheena Gillani Received Received
  PO5-8 Assessment of liver fibrosis in individuals with inflammatory bowel disease and steatotic liver disease using non-invasive tests Robert Nastasa Received Received
  PO4-9 Gender differences in the development of steatotic liver disease and fibrosis: implications for diagnosis and management Florian Koutny Received Received
  PO5-9 SMAD 3 variant rs10152544 is associated with higher fibrosis grade in metabolic steatotic liver disease (MASLD) Claudia Oliveira Received Received
  PO3-9 Staging chronic liver injury and fibrosis using the enzyme biomarkers circulating fibroblast activation protein alpha (cFAP) and cDPP4 Mark Gorrell Received Received
  PO6-9 The impact of sarcopenia on both liver and cardiovascular alterations in patients with early stages of steatotic liver disease: a sole protagonist or a co-actor with other metabolic risk factors? FLORIANA SANTOMENNA Received Received
  PO2-9 Assessing the repeatability and reproducibility of LiverMultiScan metrics cT1 and PDFF Andrea Dennis Received Received
  PO7-9 Clinical and biochemical features of diagnosed and undiagnosed patients with non-alcoholic fatty liver disease Julia Uhanova Received Received
  PO1-9 Pharmacodynamics screening of potential therapeutic substances in an experimental model of metabolic dysfunction associated steatohepatitis Mahak Arora Received Received
  PO6-10 A randomized controlled trial of Resmetirom in nonalcoholic steatohepatitis: 52-week Data From MAESTRO-NASH Peter Rydqvist Received Received
  PO5-10 Histological features distinguish alcoholic from metabolic dysfunction-associated steatohepatitis Tessa Ostyn Received Received
  PO4-10 Treatment with semaglutide affects favorably hepatic fat content but has no effect on response of liver fat to glucose and/or fructose administration Jan Kovar Received Received
  PO2-10 Hepatic steroids metabolism reflects the entity of liver damage in patients with metabolic dysfunction-associated steatohepatitis (MASH) Eleonora Dileo Received Received
  PO1-10 Persons diagnosed with metabolic dysfunction-associated steatotic liver disease are at an increased risk of severe depression in a Swedish nationwide cohort study Hanne ström Received Received
  PO7-10 GCKIII kinases in hepatocellular lipotoxicity: role in NAFLD and beyond Margit Mahlapuu Received Received
  PO3-10 Serum protein induced by vitamin k absence or antagonist II for the prediction and risk stratification of HCC development in patients with metabolic dysfunction-associated steatotic liver disease on long-term follow-up Marta Guariglia Received Received
  PO3-11 Alcohol overconsumption is common in MASLD and highly increases risk for future cirrhosis Hannes Hagström Received Received
  PO1-11 Cytokines level during the pregnancy with MASH and obesity under the developed complex therapy program Lina Bahniy Received Received
  PO4-11 In silico strategies and gene expression data indicate EFEMP1 as a potential biomarker for early fibrosis diagnosis in metabolic dysfunction-associated steatotic liver disease Allen Anthony Larańo Received Received
  PO6-11 The beneficial hepatic-effect of Glucagon-like Peptide 1 receptor agonists in diabetic patients with metabolic dysfunction-associated liver disease (MASLD) Giordano Sigon Received Received
  PO5-11 Exploring the association between quality of life, diet, physical activity, and binge eating disorder in MASLD patients in a tertiary centre of care Giordano Sigon Received Received
  PO7-11 Genetic evidence for a role of PON2 in liver fibrosis and generation of PON2 knockdown LX-2 cells Tammy Huybrechts Received Received
  PO2-11 Adherence to mediterranean diet reduces steatotic liver disease risk but does not affect liver fibrosis assessed by transient elastography: results from a prospective study Gediz Dogay Us Received Received
  PO3-12 Traditional indigenous land-based diet and non-alcoholic fatty liver disease Julia Uhanova Received Received
  PO7-12 Glutamyl aminopeptidase A (APA): a novel secreted kidney protein impacting liver homeostasis Sharleen Hamad Received Received
  PO5-12 Evaluation of non-invasive scores for monitoring liver fibrosis resolution after bariatric surgery Francois Pattou Received Received
  PO2-12 Comparison of the prognosis of patients with metabolic dysfunction-associated steatotic liver disease and alcohol-related liver disease who underwent hepatic vein catheterization imon Dostál Received Received
  PO1-12 Maternal overnutrition and increased risk of intergenerational liver disease and cancer targeting epigenetic mechanisms Claudia Bigas Received Received
  PO6-12 Association between FAST score and hepatocyte ballooning in Non- Alcoholic steatohepatitis patients: findings from EVIDENCES-X study of 393 biopsied individuals Deven Parmar Received Received
  PO2-13 Progression to cirrhosis and all-cause mortality is increased In postmenopausal women with MASLD independently of fibrosis stage at baseline Aleksandra Dunin-Borkowska Received Received
  PO6-13 Estimated glucose disposal rate correlates with histological severity of MASLD in women, but not in men Zouhir Gadi Received Received
  PO5-13 Early prediction of progressive fibrogenesis in participants with MASLD using blood-based biomarkers Koen van Son Received Received
  PO4-13 Low number needed to screen for advanced MASLD fibrosis in internal medicine and general practice Koen van Son Received Received
  PO7-13 Validation of the enhanced liver fibrosis (ELF)-test in heparinized and EDTA plasma for future reflex testing in diagnostic algorithms Koen van Son Received Received
  PO3-13 CTRP1, a novel molecular linker for hepatic glycogen and lipid metabolism ameliorates fatty liver diseases Sora Han Received Received
  PO1-13 Inflammatory landscape and metabolic profiling of the Mc4r KO mouse on a western diet to study human metabolic dysfunction associated steatohepatitis Fabienne Birrer Received Received
  PO7-14 Cholesterol exacerbates microcirculatory abnomalities in non-alcoholic fatty liver disease Evelyn Pereira Received Received
  PO3-14 Associations of the fibrosis-4 index with rates of cardiac events and liver decompensation, and the potential implications on risk stratification in patients with nonalcoholic steatohepatitis Fishman Jesse Received Received
  PO6-14 Phosphatilylethanol probe into the de-novo post-liver transplant steatotic liver disease: MASLD, or MetALD? Lubomir Skladany Received Received
  PO5-14 Impact of a 6-month dietary intervention on cognitive dysfunction and liver status in overweight/obese patients with metabolic dysfunction-associated steatotic liver disease Nuria Pérez Diaz del Campo Received Received
  PO4-14 Apolipoprotein F deficiency is associated with reduced mitochondrial function in hepatocytes Viktor LIENARD Received Received
  PO1-14 Association of hepatic fibrosis and chronic kidney disease in a real world cohort of metabolic-dysfunction associated steatotic liver disease (MASLD); implications for screening in an intelligent LFT (iLFT) platform Paul Brennan Received Received
  PO2-14 Loss of liver adrenoceptor alpha-1b exacerbates fibrosis and inflammation in mice Bernie Efole Received Received
  PO1-15 STE20-type Kinases MST3 and MST4 promote the progression of hepatocellular carcinoma Mara Caputo Received Received
  PO2-15 Hepatocellular loss of mTOR aggravates tumor burden in non-alcoholic steatohepatitis-related HCC Antje Egners Received Received
  PO6-15 Diagnostic accuracy and optimal cut-off of fibroScan controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) in assessing steatosis and fibrosis in patients with bariatric surgery and elective laparoscopic cholecystectomy Riham Soliman Received Received
  PO5-15 Metabolomics analysis showed increased metabolites and acylcarnitine concentrations before and after a lipid load in subjects with steatotic liver disease SAMANTHA PEZZICA Received Received
  PO4-15 Multiparametric liver ultrasound for non-invasive quantification of steatosis, fibrosis, ballooning and inflammation in metabolic dysfunction-associated steatotic liver disease Antonio Liguori Received Received
  PO3-15 Mechanisms underlying steatotic liver disease in mental illness: antipsychotic drugs disrupt ferroptosis signaling pathways Karen Houseknecht Received Received
  PO3-16 Serum free fatty acids in children with metabolic-associated fatty liver fibrosis Nataliya Zavhorodnia Received Received
  PO6-16 Steatotic liver disease and inflammatory bowel disease: is it all MASLD? Patricia Sousa Received Received
  PO4-16 Non-invasive assessment of cell-free circulating mtDNA and copy number open an intriguing spyhole for the diagnosis of NAFLD-HCC in genetically predisposed individuals Miriam Longo Received Received
  PO1-16 RIPK3-dependent signalling and crosstalk hepatocytes-macrophages in MASLD progression André Cardador Received Received
  PO2-16 The effect of baseline hepatic steatosis on fibrosis changes after SVR in CHC-Genotype 4 patients treated with INF, a 10-year follow-up Mohamed Elbasiony Received Received
  PO5-16 The role of genetic polymorphism in predicting of metabolic associated fatty liver disease clinical course Vasyl Prysyazhnyuk Received Received
  PO7-16 Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes Axel Wester Received Received
  PO1-17 SAMM50 affect mitochondria dynamics in high-fat related non-alcohol steatohepatitis Wan-Long Chuang Received Received
  PO7-17 The efficacy of multi-disciplinary lifestyle modifications in Taiwanese non-alcoholic steatohepatitis patients- subgroup analysis of the placebo group patients in a randomized trial Jee-Fu Huang Received Received
  PO5-17 Synergistic effect of metabolic dysfunction-associated steatotic liver disease and obesity severity in adolescents on future risk of type 2 diabetes: a cohort study Resthie R Putri Received Received
  PO6-17 Effects of sodium-glucose cotransporter 2 inhibitor versus sulfonylurea on nonalcoholic fatty liver disease and diabetes Yumie TAKESHITA Received Received
  PO2-17 Assessing the diagnostic accuracy of the fibroScan-AST (FAST) score for high-risk metabolic dysfunction-associated steatohepatitis : a diagnostic accuracy meta-analysis Muhammed Elfaituri Received Received
  PO3-17 Transition from non-alcoholic fatty liver disease to steatotic live disease: real-world evidence in a cohort of individuals with type 1 and type 2 diabetes Tammy Huybrechts Received Received
  PO6-18 Lipid and carbohydrate metabolism in children with metabolic-associated fatty liver fibrosis Nataliya Zavhorodnia Received Received
  PO4-18 Metabolic-associated steatotic liver disease and insulin-related mechanisms: insights from a cluster analysis of the PREVADIAB2 study Maria Paula Macedo Received Received
  PO5-18 Diagnostic accuracy of AGILE3 score for the non-invasive identification of patients with steatotic liver disease (SLD) and advanced fibrosis: a systematic review and meta-analysis Federico Ravaioli Received Received
  PO2-18 The hepatokine leukocyte cell-derived chemotaxin-2 is elevated in people with impaired glycaemic control and augmented by acute exercise Buket Engin Received Received
  PO7-18 Predictive ability of non-invasive fibrosis tests for long-term liver, cardiovascular and kidney outcomes in Europeans with metabolic risk factors from the UK Biobank Federica Tavaglione Received Received
  PO1-18 Improvement of HRQoL features and liver status after a 6-month dietary intervention in patients with metabolic dysfunction-associated steatotic liver disease Gabriele Castelnuovo Received Received
  PO3-18 The effect of dapagliflozin on fibrosis and inflammation in patients with metabolic dysfunction-associated steatohepatitis Elena Laura Iliescu Received Received
  PO5-19 Combining diabetes, sex and menopause as meaningful clinical features associated with NASH and moderate-to-advanced liver fibrosis in uned individuals with class II and III obesity: a retrospective cohort study Violeta Raverdy Received Received
  PO4-19 Depression, anxiety, worry and emotional dysregulation in compensated advanced chronic liver disease Eleonora Maggio Received Received
  PO3-19 High tyrosine and PLIN2 and low beta-hydroxybutyrate characterize subjects with metabolic dysfunction-associated steatohepatitis (MASH) Patrizia Infelise Received Received
  PO1-19 From old to new: assessing the accuracy of non-invasive tests of fibrosis in patients with metabolic associated fatty liver disease and excessive alcohol consumption according to the recent definition Annalisa Cespiati Received Received
  PO2-19 Comparison between transient elastography and shear wave elastography for assessment of liver fibrosis in Egyptian patients with NAFLD: a single center experience Ahmed/ El Fayoumi Received Received
  PO-20 Draft 1 Carlos Vidal Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
13:20
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

SLD Summit 2023

 

21-23 September Prague
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 21/09/2023 TO 21/09/2024
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                  




PosterSessionOnline
Logo Draft
 
Logo Cert